ArticleNature communications2017
Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Age- and tissue-dependent diversity of human plasmacytoid dendritic cells uncovers a cycling subset dominant in early life and cancer.Immunity · 2026Article
- A "Vascular Band-Aid" strategy for proactive inhibition of post-anastomotic vascular complications.Regenerative biomaterials · 2026Article
- Curdione combined with borneol treats bacterial mixed HPV infection by regulating the crosstalk among immune cells.Frontiers in immunology · 2025Article
- CXCR4: from B-cell development to B cell-mediated diseases.Life science alliance · 2024Review
- The histamine analogue clobenpropit modulates IRF7 phosphorylation and interferon production by targeting CXCR4 in systemic lupus erythematosus models.Frontiers in immunology · 2024Article
- The story of clobenpropit and CXCR4: can be an effective drug in cancer and autoimmune diseases?Frontiers in pharmacology · 2024Review
- Spermine and spermidine bind CXCR4 and inhibit CXCR4- but not CCR5-tropic HIV-1 infection.Science advances · 2023Article
- Toll-like Receptor Response to Human Immunodeficiency Virus Type 1 or Co-Infection with Hepatitis B or C Virus: An Overview.International journal of molecular sciences · 2023Review
- Discovery of Bis-Imidazoline Derivatives as New CXCR4 Ligands.Molecules (Basel, Switzerland) · 2023Article
- Immunometabolism of dendritic cells in health and disease.Advances in immunology · 2023Review
- Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis.Frontiers in immunology · 2023Article
- CXCR4 as a novel target in immunology: moving away from typical antagonists.Future drug discovery · 2022Review
- Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.The journal of allergy and clinical immunology. In practice · 2022Article
- Type I Interferon Production of Plasmacytoid Dendritic Cells under Control.International journal of molecular sciences · 2021Review
- CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment.Frontiers in oncology · 2021Review
- Plasmacytoid dendritic cells promote acute kidney injury by producing interferon-α.Cellular & molecular immunology · 2021Article
- CXCL12 Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021Review
- Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2020Article
- Cutaneous and systemic connections in lupus.Current opinion in rheumatology · 2020Review
- Interplay between SARS-CoV-2 and the type I interferon response.PLoS pathogens · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 4 countries.
Funding
Abstract
Plasmacytoid dendritic cells (pDC) are specialized in secretion of type I interferon in response to pathogens. Here we show that natural monoamines and synthetic amines inhibit pDC activation by RNA viruses. Furthermore, a synthetic analogue of histamine reduces type I interferon production in a mouse model of influenza infection. We identify CXC chemokine receptor 4 (CXCR4) as a receptor used by amines to inhibit pDC. Our study establishes a functional link between natural amines and the innate immune system and identifies CXCR4 as a potential 'on-off' switch of pDC activity with therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.